Thursday, September 22
Perspectives on risk
Judie Leach Bennett, Candian Blood Services
Risk-based decision making for blood safety: An international consensus conference – report and future steps. Presentation
Mark W. Skinner, World Federation of Hemophilia
MSM donor deferral. Presentation
Nathan Schaefer, MSSA, Gay Men’s Health Crisis
Advocacy to revise blood donation policies for MSM. Presentation
Steven Kleinman, Blood Systems Research Institute
HIV data from a multicenter efficacy study of HIV, HCV, and HBV blood screening scenarios. Presentation
Achieving a safe and affordable supply
Health technology assessment in hemophilia
Albert Farrugia, Plasma Protein Therapeutics Association
Hemophilia and health technology assessment. Presentation
Update on inhibitors
J. Michael Soucie, Centers for Disease Control and Prevention
Update on studies of inhibitors. Presentation
Carol K. Kasper, University of Southern California
How do we define a (clinically-relevant) inhibitor? Presentation
Corien Eckhardt, INSIGHT investigators
Inhibitor development in mild/moderate hemophilia A. Presentation
Elena Santagostino, Milan, Italy
SIPPET and EUHASS studies. Presentation
Clinica trial issues
Jerry S. Powell, Hemostasis and Thrombosis Center, University of California Davis
New products for treatment of hemophilia ‒ changing options and clinical trial design. Presentation
Donna Di Michele, project group of the FVIII/IX subcommittee
Clinical trial design for hemophilia. Presentation
Alok Srivastava, on behalf of the FVIII/IX sub-committee SSC-ISTH project group
Potency assignment of clotting factor concentrates. Presentation
Friday, September 23
Novel technologies
Magdy El Ekiaby, Shabrawishi Hospital BTC
SD Cryoprecipitate: Clinical experience update. Presentation
Manufacturer's updates
Debra Bensen-Kennedy, CSL Behring
Pioneering designs for recombinant coagulation factors. Presentation
Prasad Mathew, Bayer
Novel treatment options for hemophilia treatment. Presentation
Snejana Krassova, Biogen Idec Hemophilia
Research update. Presentation
Kim Jacobsen, Novo Nordisk
Manufacturing, efficacy and safety of recombinant FXIII. Presentation
Other presentations to be posted later.
Last Updated October 2011 |
